FCRC Contract Will Be Completed In Five Parts, Two of Them For Small Business; RFP Available July 24
In Brief: Chabner Names DCT Acting Director, Schepartz Returns To Deputy Job; GM Winners Announced
DCT Board Approves Concepts Of Eight New Biological Response Modifiers Program
FDA Committee Oks AMSA for Group C List, Tables THC Request, Deadlocks On Estramustine NDA
NTP Panel Agrees PBB Carcinogenic, Two Asbestos Varieties Are Not
Trending Stories
- Is it time to re-assess the practice and practicality of screening colonoscopy?
Modeling data, ACS guideline support greater use of noninvasive tests to ease system strain, help save lives - The Directors: Two Gulf Coast cancer center directors on why NCI designation matters—and why they want it
Lucio Miele and Raghu Kalluri: Science and technology have changed what an aspiring cancer center must accomplish - From “default dead” to living the future of cancer care
As founding CEO of GitLab, I went “founder mode” on my osteosarcoma - Brian Wolpin celebrates FDA approval of daraxonrasib in pancreatic cancer as the future of the field
- FDA advisory committee votes in favor of Galleri approval, but calls for removal of “early” detection claims
Clinical benefit will not be considered for approval, FDA says - Trump weighs—and abandons—an executive order that would give OMB veto power over NIH grants
